Hoping Drugs Take Root, Alder Raises $38 Million Round

The Bothell, Wash.-based antibody developer will study a Phase II interleukin-6 inhibitor in cancer indications, and will bring a new migraine drug into the clinic. The IL-6 drug is already partnered with BMS in a lucrative deal for autoimmune indications.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America